Biosimilar antibodies are research-grade antibodies that are highly similar in structure, function and sequences to the approved original therapeutic antibodies. They are produced through recombination technology and have the same variable regions from the corresponding therapeutic antibodies, which making them reliable and more cost-effective research tools and alternative reagents in drug development and basic research.
CUSABIO has successfully expressed and validated many research-grade biosimilar antibodies, covering a variety of popular targets. All these research-grade biosimilar antibodies can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
Our biosimilar antibodies are recombinantly expressed in mammalian cells with unmodified variable and Fc regions identical to the approved therapeutic antibodies.
We offer over 200 ready-to-use biosimilar antibodies covering key targets, including immune checkpoints, tumor drivers, and neurological markers.
Each batch is ELISA-validated for strong target binding and comes with an EC50 value for reliable performance.
We offer stable supply of research-grade biosimilar antibodies from ul to g level, proving multiple options to customers.
Serve as highly similar research tools for in vitro assessment of biological activities such as cytotoxicity and blocking effects of antibody drugs, enabling in-depth investigation into their mechanisms of action.
Used as critical reference standards or surrogate materials in the development of pharmacokinetic (PK) and immunogenicity (ADA) assays, facilitating method validation and bioequivalence evaluation.
Function as reliable positive controls in Flow Cytometry, IHC, and other detection platforms, or are utilized in the development of companion diagnostics to ensure assay specificity and accuracy.
With formulations suitable for in vivo administration, they can be directly applied in animal models for efficacy assessment and dose exploration, providing a foundation for preclinical research.
| Code | Product Name |
|---|---|
| CSB-RA159341MB20HU | EGFR (Tomuzotuximab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA017647MB13HU | PCSK9 (Frovocimab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA614985MB1HU | AMHR2 (Murlentamab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA675446MB18HU | TIGIT (Tamgiblimab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA012719MB16HU | LAG3 (Ieramilimab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA619964MB54HU | PDCD1 (Acrixolimab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA878862MB3HU | DLL4 (Enoticumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA887154MB1HU | RSPO3 (Rosmantuzumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA015215MB3HU | MUC1 (Gatipotuzumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA013714MB5HU | MET (telisotuzumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA015949MB1HU | NOTCH1 (Brontictuzumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA001950MB17HU | APP (Ponezumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA890692MB1HU | EGFL7 (Parsatuzumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA011088MB1HU | IGF2 (Dusigitumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA006163MB19HU | CTLA4 (Nurulimab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA004936MB26HU | CD40 (Bleselumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA004935MB11HU | CD4 (Priliximab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA624104MB14HU | IL17A (Perakizumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA007717MB4HU | EPCAM (Adecatumumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA008645MB2HU | FGFR2 (Aprutumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA017647MB12HU | PCSK9 (Ralpancizumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA011649MB7HU | IL2RA (Camidanlumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA025399MB1HU | TYRP1 (Flanvotumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA011590MB8HU | IL13 (Abrezekimab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA015511MB3HU | NCAM1 (Lorvotuzumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA001347MB1HU | ADCYAP1R1 (Zelminemab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA017647MB11HU | PCSK9 (Lodelcizumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA023954MB1HU | TNC (Tenatumomab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA015056MB1HU | MST1R (Narnatumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA012719MB15HU | LAG3 (Encelimab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA011649MB6HU | IL2RA (Inolimomab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA004935MB10HU | CD4 (Cedelizumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA006240MB3HU | CXCL10 (Eldelumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA159341MB19HU | EGFR (Depatuxizumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA011590MB7HU | IL13 (Anrukinzumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA004943MB3HU | CD52 (Gatralimab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA890691MB1HU | STEAP1 (Vandortuzumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA004888MB12HU | CD19 (Coltuximab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA005166MB1HU | CEACAM6 (Tinurilimab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA007765MB8HU | ERBB3 (Patritumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA004936MB25HU | CD40 (Teneliximab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA011087MB13HU | IGF1R (Dalotuzumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA010958MB1HU | ICOSLG (Prezalumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA001950MB16HU | APP (Solanezumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA004954MB5HU | CD70 (Vorsetuzumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA023446MB3HU | TGFB1 (Metelimumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA004935MB9HU | CD4 (Clenoliximab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA011087MB12HU | IGF1R (Figitumumab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA006045MB5HU | CSF2 (Otilimab Biosimilar) Recombinant Monoclonal Antibody |
| CSB-RA159341MB17HU | EGFR (Zalutumumab Biosimilar) Recombinant Monoclonal Antibody |